New hope for advanced prostate cancer: STAMPEDE2 trial tests targeted therapies
NCT ID NCT06320067
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This large Phase 3 trial tests whether adding targeted radiotherapy (SABR) or a radioactive drug (PSMA-Lutetium) to standard hormone therapy can slow cancer spread and improve survival in people with metastatic prostate cancer. About 3,360 participants across the UK will be randomly assigned to receive standard care alone or with one of the new treatments. The study monitors side effects and cancer progression over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Addenbrookes
RECRUITINGCambridge, United Kingdom
-
Barking, Havering and Redbridge University Hospitals NHS Trust
RECRUITINGRomford, United Kingdom
-
Barts Health NHS Trust
RECRUITINGLondon, United Kingdom
-
Churchill Hospital
RECRUITINGOxford, United Kingdom
-
Derriford Hospital
RECRUITINGPlymouth, United Kingdom
-
Kings Mill Hospital
RECRUITINGSutton in Ashfield, United Kingdom
-
Mount Vernon Hospital
RECRUITINGBarnsley, United Kingdom
-
North Middlesex Hospital
RECRUITINGLondon, United Kingdom
-
North Tees Health NHS Trust
RECRUITINGStockton-on-Tees, United Kingdom
-
Queen Alexandra Hospital
RECRUITINGPortsmouth, United Kingdom
-
Royal Devon & Exeter Hospital
RECRUITINGExeter, United Kingdom
-
Royal Devon University Hospital Trust
RECRUITINGExeter, EX2 5DW, United Kingdom
-
Royal Free Hospital
RECRUITINGLondon, United Kingdom
-
The James Cook University Hospital
RECRUITINGMiddlesbrough, United Kingdom
-
The Princess Alexandra Hospital
RECRUITINGHarlow, United Kingdom
-
The Royal Marsden Hospital
RECRUITINGLondon, SW3 6JJ, United Kingdom
-
The Royal Marsden Hospital
RECRUITINGSutton, SM2 5PT, United Kingdom
-
University College London Hospitals NHS Foundation Trust
RECRUITINGLondon, NW3 2PG, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill outsmart resistant prostate cancer?
- Could fasting help the immune system fight prostate cancer?
- Could a new PET tracer reveal hidden prostate cancer activity?
- New imaging comparison could improve prostate cancer monitoring
- AI reads biopsies to predict cancer spread
- AI learns from 14,000 prostate scans to spot aggressive cancers